Insulet Corp (PODD)
Health Care · Health Care Equipment · US stock · S&P 500 component
$141.10
▲ +2.33 (1.68%)
Fair valueFair
$169 +19.7% to fair value
$84fair band $101–$236$253
Day's range
$140.22 – $143.31
52-week range
$126.40 – $354.88
About Insulet Corp
Insulet develops and sells the Omnipod, a small wearable insulin delivery device that people with diabetes attach to the body instead of using injections or a tubed pump. Revenue comes mainly from recurring sales of disposable pods, which are replaced regularly, along with the companion controller software. Products reach patients through pharmacies, distributors and healthcare providers, with reimbursement from insurers playing a central role in the business.
Revenue of $3.1 billion was recorded for the latest twelve months; sales grew 27.5% a year over the past three years. Insulet Corp converts that into an operating margin of 16.9%. Return on invested capital comes to 21%. Net debt to EBITDA is 0.7 times. It does not pay a dividend, and the X-Ray Score is 70 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $126.40 – $354.88Volume 1,618,300Daily, split-adjusted
Vitals
Market cap$9.8B
52-week range$126.40 – $354.88
Volume (last day)1,618,300
P/E (TTM)26.5
EBIT / EV yield5.1%
Free-cash-flow yield3.0%
Dividend yieldNo dividend
Revenue (TTM)$3.1B
Net income (TTM)$375M
Operating margin16.9%
Return on capital21.3%
Debt incl. leases$948M
Cash & securities$535M
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
$169model spread $109 – $160
Fair
+19.7% to fair value
Equal blend of three models: peer multiples, a fundamentals-adjusted multiple (growth, ROIC and margin) and a 10-year DCF scaled to the market's average. Earnings-power value (no growth) is a floor and not part of the blend. Model uncertainty is High, so the safety margin is 40%.
Multiples use through-the-cycle earnings (0.61x of the last twelve months)
Peak-cycle earnings: the current operating margin is more than 1.5x its 7-year average, so the fair value range is widened
Price $141
Undervalued < $101Fair $101 – $236Overvalued > $236
10-year DCF (market-scaled)
$288
Peer multiples
$89
Earnings power floor (not blended)
$41
Fundamentals-adjusted multiple
$129
Growth the price implies
15.9%/yr
A model estimate, not a price target or recommendation. Inputs: risk-free 5.09%, equity risk premium 4.23% (Damodaran). How it works.
What this means
Average business, fairly priced
The price sits inside our fair-value band. A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Fair
58/100
Priced about in line with its sector.
See the numbers →
EBIT / EV yield5.1%
Free-cash-flow yield3.0%
Fair value vs price1.2×
Growth
Strong
91/100
Growing faster than most of its sector.
See the numbers →
Revenue growth (3y)27.5%
EPS growth (3y)267.7%
Growth consistency100%
Profitability
Fair
64/100
Returns on capital are typical for its sector.
See the numbers →
Return on invested capital21.3%
Operating margin16.9%
Gross profitability68.6%
Financial health
Fair
67/100
Balance sheet is in typical shape for its sector.
See the numbers →
Piotroski F-Score7 / 9
Net debt / EBITDA0.7×
Interest cover8.8×
Dividends
None
–/100
Pays no dividend.
See the numbers →
Quarterly results: last 6 quarters
+28.8%
Mar '25
+32.9%
Jun '25
+29.9%
Sep '25
+31.2%
Dec '25
+33.9%
Mar '26
+23.5%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $802M, diluted EPS $1.37.
Compare with peers
RMD Resmed Inc73 DXCM Dexcom Inc71 IDXX Idexx Laboratories Inc67 STE STERIS plc64Other Health Care Equipment companies by X-Ray Score.
Fundamentals checklist
● 10 Good · ● 4 Average · ● 1 BadCash quality
Earnings backed by cashAverage
Free-cash-flow yieldBad
Risk models
Altman Z''Good
Piotroski F-ScoreAverage
Growth
EPS growth (3y)Good
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioGood
Net debt / EBITDAGood
Interest coverAverage
Valuation
Fair value vs priceGood
EBIT / EV yieldGood
Profitability
Return on invested capitalGood
Operating marginAverage
Gross profitabilityGood
Each check is graded against the company's sector, not a fixed number. Checklist score 71/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $1.1B | $1.3B | $1.7B | $2.1B | $2.7B |
| Operating income | $126M | $38M | $220M | $309M | $474M |
| Net income | $17M | $5M | $206M | $418M | $247M |
| Operating cash flow | −$68M | $119M | $146M | $430M | $569M |
| Operating margin | 11.5% | 2.9% | 13.0% | 14.9% | 17.5% |
| Free cash flow | −$180M | −$4M | $70M | $305M | $378M |
| Diluted EPS | $0.24 | $0.07 | $2.94 | $5.78 | $3.48 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bearish
6 bullish · 1 neutral · 9 bearish
Weekly
Strongly bearish
1 bullish · 1 neutral · 10 bearish
Monthly
Strongly bearish
0 bullish · 1 neutral · 7 bearish
Moving averages (daily)
| SMA 10 | 136.6 | Bullish |
| EMA 10 | 137.1 | Bullish |
| SMA 20 | 135.7 | Bullish |
| EMA 20 | 137.1 | Bullish |
| SMA 50 | 140.4 | Bullish |
| EMA 50 | 141.5 | Bearish |
| SMA 100 | 147.7 | Bearish |
| EMA 100 | 153.6 | Bearish |
| SMA 200 | 185.8 | Bearish |
| EMA 200 | 182.1 | Bearish |
Oscillators (daily)
| RSI (14) | 55.58 | Neutral |
| MACD (12, 26) | -0.81 | Bearish |
| Momentum (12) | 8.15 | Bullish |
| Stochastic %K (14) | 85.56 | Bearish |
| Williams %R (14) | -14.44 | Bearish |
| CCI (20) | 152.5 | Bearish |
Pivot points (classic, last session)
S3 136.7 | S2 138.5 | S1 139.8 | Pivot 141.5 | R1 142.9 | R2 144.6 | R3 146.0 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
PODD SEC filings
21 Sep 2026
8-KSEC EDGAR
Entered a material agreement
16 Sep 2026
8-KSEC EDGAR
Director or officer change
10 Sep 2026
8-KSEC EDGAR
Director or officer change
5 Aug 2026
10-QSEC EDGAR
Quarterly report
5 Aug 2026
8-KSEC EDGAR
Results of operations
25 Jun 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
26 May 2026
8-KSEC EDGAR
Regulation FD disclosure
21 May 2026
8-KSEC EDGAR
Shareholder vote results
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.